TY - JOUR
T1 - Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)?
AU - Kunchok, Amy
AU - Krecke, Karl N.
AU - Flanagan, Eoin P.
AU - Jitprapaikulsan, Jiraporn
AU - Lopez-Chiriboga, A. Sebastian
AU - Chen, John J.
AU - Weinshenker, Brian G.
AU - Pittock, Sean J.
N1 - Funding Information:
A. Kunchok has previously received research support from Biogen. K. Krecke, J. Jitprapaikulsan, A. Lopez-Chiriboga and J. Chen report no disclosures. E. Flanagan is a site principal investigator in a randomized placebo-controlled clinical trial of Inebilizumab (A CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio. B. Weinshenker receives royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr. Volkmann und Kollegen GbR for a patent of NMO-IgG as a diagnostic test for NMO and related disorders; served on adjudication committee for clinical trials in NMO conducted by MedImmune and Alexion; and consulted for Caladrius Biosciences, Roivant, Brainstorm Therapeutics, Chugai, and Mitsubishi Tanabe regarding clinical trials for NMO. S. Pittock reports grants, personal fees, and nonfinancial support from Alexion Pharmaceuticals, Inc.; grants from Grifols and Autoimmune Encephalitis Alliance; grants, personal fees, nonfinancial support, and other from MedImmune, Inc. Dr. Pittock has a patent #9,891,219 (Application# 12-573942) “Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive.” Go to Neurology.org/N for full disclosures.
Publisher Copyright:
© American Academy of Neurology.
PY - 2020/1/14
Y1 - 2020/1/14
N2 - Myelin oligodendrocyte glycoprotein-IgG is a biomarker associated with CNS demyelinating diseases.1,2 MOGAD and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) have overlapping clinical features including optic neuritis and myelitis. However, there are several clinical and radiologic distinguishing features of MOGAD including lack of female predominance, higher incidence of acute disseminated encephalomyelitis (ADEM), higher proportion of bilateral optic neuritis, and T2-signal confined to gray matter and conus involvement in myelitis.1,3,4
AB - Myelin oligodendrocyte glycoprotein-IgG is a biomarker associated with CNS demyelinating diseases.1,2 MOGAD and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) have overlapping clinical features including optic neuritis and myelitis. However, there are several clinical and radiologic distinguishing features of MOGAD including lack of female predominance, higher incidence of acute disseminated encephalomyelitis (ADEM), higher proportion of bilateral optic neuritis, and T2-signal confined to gray matter and conus involvement in myelitis.1,3,4
UR - http://www.scopus.com/inward/record.url?scp=85077800928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077800928&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000008786
DO - 10.1212/WNL.0000000000008786
M3 - Article
C2 - 31827002
AN - SCOPUS:85077800928
SN - 0028-3878
VL - 94
SP - 85
EP - 88
JO - Neurology
JF - Neurology
IS - 2
ER -